Hansa Biopharma Interim Report January-September 2019
MALMÖ, Sweden, Oct. 31, 2019 /PRNewswire/ — – Positive results from a pooled analysis of Phase 2 trials with imlifidase for desensitization in highly sensitized kidney transplant patients were presented for the first time at the European Society of Organ Transplantation’s (ESOT) Congress…
Comments Off on Hansa Biopharma Interim Report January-September 2019